ArticleIranian journal of pharmaceutical research : IJPR

Cost-Utility Analysis of Trastuzumab-Emtansine Versus Trastuzumab for the Treatment of Residual Invasive HER-2-Positive Breast Cancer in Iran.

Homa Hemati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.